Biogen receives priority review for Alzheimer’s drug candidate
Biogen (BIIB) announced that the FDA has accepted its Biologics License Application for aducanumab. The application has been granted Priority Review and its PDUFA date has been set at March 7, 2021. The agency has stated that it may take earlier action than the date. The company is collaborating with Eisai Co. Ltd. of Japan for developing this investigational treatment for Alzheimer’s disease.
Aducanumab has the potential to become the first treatment to bring significant change in the course of the disease for patients. The